Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.

NCT04064697 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Saint Etienne as lead sponsor.

NCT NCT04064697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04064697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative Colitis (UC) Requiring Vedolizumab Therapy: a Randomized Clinical Trial Comparing a Strategy With or Without Antiviral Therapy.
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Phase
Phase 3
Overall status
Terminated
Start date
April 22, 2021
Completion date
February 8, 2024
Enrollment
6 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis, unspecified